Du är här

2015-09-11

Swedish Orphan Biovitrum AB (publ) : The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitme

The annual general meeting ofSwedish Orphan Biovitrum AB(publ) on 30 June 2015
resolved - for the purpose of ensuring that the company can fulfil its
commitments under the long-term incentive programme resolved by the annual
general meeting - on a directed share issue of no more than 1,036,856
redeemable- and convertible class C shares.

The general meeting also resolved to authorise the board of directors to
resolve on the repurchase of all issued class C shares by an offer directed
to all holders of class C shares. Repurchase under this authorisation may be
made on one or several occasions until the annual general meeting in 2016 and
at a price to no less than 100 per cent and no more than 105 per cent of the
quotient value of the share (approximately SEK 0.55).

The board of directors has resolved to exercise the repurchase authorisation
for the said purpose by repurchasing of all issued class C shares against
payment of 100 per cent of the quotient value of the share, corresponding to
approximately SEK 0.55 per share. Repurchase of the class C shares may be
effected during the period 11 September - 27 September 2015.

The company currently holds 2,763,768 own common shares and 396,180 own class
C shares. Subsequently to the effected repurchase of class C shares above,
the number of own class C shares will amount to 1,433,036.

The class C shares will, following the repurchase, be converted to common
shares in the number that is required to ensure delivery under the incentive
programme.

---

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on
NASDAQ OMX Stockholm. More information is available atwww.sobi.com.

For more information please contact

----------------------------------------------------------------------------------------------------
| Media relations Investor relations |
| Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| oskar.bosson@sobi.com jorgen.winroth@sobi.com |
----------------------------------------------------------------------------------------------------

The information was released for public distribution on 11 September 2015 at
08:30 CET.

034e_Repurchase of shares
http://hugin.info/134557/R/1951205/709530.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1951205

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.